Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mateon Reports First Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif. , May 15, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, announced today financial results for the first quarter of 2019.
View HTML
Toggle Summary Mateon and Oncotelic Complete Their Merger and Create a New Immuno-Oncology Company with a Late-Stage Clinical Asset Against Cancer and a Promising Product Pipeline
-Merger creates a publicly-traded clinical stage immuno-oncology company developing treatments for advanced cancers including aggressive brain tumors, pancreatic cancer, and melanoma   -Phase 2 clinical data on lead product candidate OT-101 demonstrated robust tumor responses including complete
View HTML
Toggle Summary Mateon Enters into Merger Agreement with Oncotelic
Forms Late Clinical-Stage Cancer Immunotherapy Company Focusing on TGF-β RNA Therapeutics SOUTH SAN FRANCISCO, Calif. and AGOURA HILLS, Calif. , April 18, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) and Oncotelic Inc. , a privately-held, late clinical-stage cancer immunotherapy
View HTML
Toggle Summary Mateon Therapeutics Reports Third Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced third quarter 2018 financial results.  For the three months ended
View HTML
Toggle Summary Mateon Therapeutics to Present at the Rodman & Renshaw Investor Conference on September 6, 2018
SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing drugs for the treatment of orphan oncology indications, today announced it will provide an overview of the company and its programs at the 20 th Annual
View HTML
Toggle Summary Mateon Therapeutics Receives Notice of Partial Clinical Hold for OX1222 Study
SOUTH SAN FRANCISCO, Calif. , Aug. 17, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced that the U.S. Food and Drug Administration (FDA) placed a partial
View HTML
Toggle Summary Mateon Therapeutics Reports Second Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced second quarter 2018 financial results.  For the three months ended
View HTML
Toggle Summary Mateon Therapeutics Reports First Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif. , May 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced first quarter 2018 financial results.  For the three months ended
View HTML
Toggle Summary Mateon Therapeutics Provides Business Update and Reports 2017 Financial Results
SOUTH SAN FRANCISCO, Calif. , April 16, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today provided a business update and announced 2017 financial results.  Business
View HTML
Toggle Summary Mateon Therapeutics Raises Net Proceeds of Approximately $2.4 Million in Financing Transaction
SOUTH SAN FRANCISCO, Calif. , April 16, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced that it has completed a private placement transaction with
View HTML